


| business Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment PR Newswire Asia |
|
SONGDO, South Korea and SAN FRANCISCO April 10, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody (mAb) program.
Posted: 2020-04-10 06:00:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.